Why Are Clinical Development Success Rates Falling?

Is biopharma continuing to become less successful in clinical development? What are the underlying reasons dragging success rates down and can they be mitigated? What does this mean for R&D productivity and the return on investment on pipeline spend?

First Name *

Last Name *

Company *

Job Title *

Department

Business Email Address *

Country *

Business Phone *

How Can We Help

fieldlabel

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Related resources

APR 08, 2024

Report

Commercial

Q2 2024 Outlook Report

Discover the catalysts, deals and likelihood of approval for 22 key drugs, devices and diagnostics expected to occur in Q2 2024.

White paper

Clinical

R&D Annual Review

The 32nd edition of our comprehensive R&D climate report. We've analyzed over 22,000 drugs in development to help you determine where the outlook is sunny, and where the storm clouds are gathering.

MAR 28, 2024

White paper

Commercial

2023 Deal-making Roundup

An overview of alliance, M&A, and financing deal activity across the
worldwide biopharma, medical device, and in vitro diagnostics
industries in 2023

View all resources